Serum PON1 arylesterase activity in relation to hyperhomocysteinaemia and oxidative stress in young adult central retinal venous occlusion patients

Eye

Volumn 22, Issue 7, 2008, Pages 969-974

  Angayarkanni, N ^a   Barathi, S ^a   Seethalakshmi, T ^a   Punitham, R ^a   Sivaramakrishna, R ^a   Suganeswari, G ^a   Tarun, S ^a  

^a VISION RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; HOMOCYSTEINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; OXIDATIVE STRESS; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 48049114151     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6703062     Document Type: Article

References (32)

1. Kazemi MB, Eshranghian K, Omrani GR, Lankarani KB, Hosseini E. Homocysteine level and coronary artery disease. Angiology 2006; 57(1): 9-14.
2. Jakubowski H. Homocysteine thiolactone: Metabolic origin and protein homocysteinylation in humans. J Nutr 2000; 30: 377S-381S.
3. Beltowski J. Protein homocystemylation: A new mechanism of atherogenesis? Postepy Hig Med Dosw (online) 2005; 59: 392-404.
4. Jakubowski H. Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease. Clin Chem Lab Med 2005; 43(10): 1011-1014.
5. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005; 24(4): 493-519.
6. Lattanzio R, Sampirtro F, Ramonia A, Fattorini A, Brancato R. Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina 2006; 26: 65-70.
7. Yildirim C, Yayali V, Tatlipinar S, Kaptanoglu B, Akpinar S. Hyperhomocysteinemia: A risk factor for retinal vein occlusion. Ophthalmologica 2004; 218:102-106.
8. Parodi MB, Di Crecchio L. Hyperhomocysteinemia in central retinal vein occlusion in young adults. Semin Ophthalmol 2003; 18: 154-159.
9. Angayarkanni N, Barathi S, Coral K, Punitham R, Ramakrishnan S, Tarun S et al. Hyperhomocysteinemia and low methionine stress are risk factors for Central Retinal Venous Occlusion in an Indian population. Invest Ophthalmol Vis Sci 2007; 48: 1441-1446.
10. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Dul BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its function. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101(8): 1581-1590.
11. Domagala TB, Łacinski M, Trzeciak WH, Mackness B. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell Mol Biol 2006; 52 (5): 4-10.
12. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21(4): 473-480.
13. Yeunga DT, Josseb D, Nicholsona JD, Khanalc A, McAndrewc CW, Bahnsonc BJ et al. Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model. Biochim Biophys Acta 2004; 1702: 67-77.
14. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135.
15. Baskol G, Karakucuk S, Oner AO, Baskol M, Kocer D, Mirza E et al. Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica 2006; 220: 12-16.
16. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991; 19(1): 100-106.
17. Liao F, Zhu X-Y, Wang Y-M, Zhao Y-S, Zhu L-P, Zuo Y-P. Correlation of serum arylesterase activity on phenylacetate estimated by the integrated method to common classical biochemical indexes of liver damage. J Zhejiang Univ Sci B 2007; 8(4): 237-241.
18. Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, Getz GS. Serum paraoxonase: Effect of apolipoprotein composition of HDL and the acute phase response. J Lipid Res 2003; 44: 780-792.
19. Devasagayam TP, Tarachand U. Decrease in lipid peroxidation in the rat kidney during gestation. Biochem Biophys Res Commun 1987; 145 (1): 134-138.
20. Ledwozyw A, Michalak J, Stepień A, Kadziolka A. The relationship between plasma triglycerides, cholesterol, total lipids and lipid peroxidation products during human atherosclerosis. Clin Chim Acta 1986; 155: 275-284.
21. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46: 1239-1247.
22. van Himbergen TM, Roest M, de Graaf J, Jansen EH, Jansen M, Hattori H et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res 2005; 46: 445-451.
23. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000; 275(6): 3957-3962.
24. Pasca SP, Nemes B, Vlase L, Gagyi CE, Dronca E, Miu, AC et al. High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sci 2006; 78: 2244-2248.
25. Goa W, Wang YS, Zhang P,Wang HY. Hyperhomocyeinemia and low plasma folate as risk factor for CRVO, Case control study in Chinese population. Grafes Arch Clin Exp Opthalmol 2006; 244: 1246-1249.
26. Karakucuk S, Baskol G, Oner AO, Baskol M, Miza E, Ustdal M. Serum paraoxonase activity is decreased in the active stage of Behcet's disease. Br J Ophthalmol 2004; 88(10): 1256-1258.
27. Hashim Z, Zarina S. Assessment of paraoxonase activity and lipid peroxidation levels in diabetic and senile subjects suffering from cataract. Clin Biochem 2007; 40(9-10): 705-709.
28. Kerkeni M, Addad F, Chauffert M, Chuniaud L, Miled A, Trivin F et al Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem 2006; 39(8): 821-825.
29. Martin SC, Butcher A, Martin N, Farmer J, Dobson PM, Bartlett WA et al. Cardiovascular risk assessment in patients with retinal vein occlusion. Br J Ophthalmol 2002; 86: 774-776.
30. Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hermost 2000; 26(3): 341-348.
31. Calla MS, Lynch SM. Vitamin C preserves the cardio-protective paraoxonase activity of high-density lipoprotein during oxidant stress. Arch Biochem Biophy 2006; 452(2): 129-137
32. Abu-Amsha R, Croft KD, Puddey IB, Proudfood JM, Beilin LJ. Phenolic content of various beverages determines the extent of inhibition of human serum and low-density lipoprotein oxidation in vitro: identification and mechanism of action of some cinnamic acid derivatives from red wine. Clin Sci 1996; 91(4): 449-458.